LYRA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.69%

Insider Buying (Last 12 Months): $74,000.00

Insider Selling (Last 12 Months): $0.00

Lyra Therapeutics Insider Trading History Chart

Lyra Therapeutics Share Price & Price History

^$0.26

▼ -0.02 (-7.17%)

As of 11/1/2024 01:00 AM ET

Days: 30 | 90 | 365

True paradigm shift

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Lyra Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2023	Harlan Waksal	Insider	Buy	25,000	$2.96	$74,000.00	261,966
5/31/2023	Nbvm Gp, Llc	Major Shareholder	Buy	1,805,416	$2.43	$4,387,160.88	2,521,745
5/31/2023	Perceptive Advisors Llc	Director	Buy	3,610,832	$2.49	$8,990,971.68	11,469,117
6/10/2022	C. Ann Merrifield	Director	Buy	4,000	$5.05	$20,200.00	11,328
5/16/2022	C. Ann Merrifield	Director	Buy	328	$5.00	$1,640.00	7,328
5/13/2022	C. Ann Merrifield	Director	Buy	3,500	$4.81	$16,835.00	7,000
4/12/2022	Edward T Anderson	Director	Buy	118,483	$4.22	$499,998.26	118,483
4/12/2022	Harlan Waksal	Insider	Buy	236,966	$4.22	$999,996.52	236,966
4/12/2022	Nbvm Gp, Llc	Major Shareholder	Buy	2,369,667	$4.22	$9,999,994.74	1,855,443

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Lyra Therapeutics (NASDAQ:LYRA)

95.62% of Lyra Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Lyra Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/6/2024	Acadian Asset Management LLC	985,631	$0.27M	0.0%	N/A	1.617%
7/12/2024	Rosalind Advisors Inc.	1,034,773	$0.29M	0.2%	-9.6%	1.697%
5/17/2024	Ikarian Capital LLC	1,056,829	$6.57M	0.7%	-15.7%	1.733%
5/10/2024	Vanguard Group Inc.	1,481,481	$9.22M	0.0%	+38.3%	2.430%
4/25/2024	Rosalind Advisors Inc.	1,144,524	$7.12M	6.7%	-39.4%	1.916%
2/15/2024	Parkman Healthcare Partners LLC	754,885	$3.96M	0.6%	+20.8%	1.436%
2/14/2024	Vestal Point Capital LP	3,000,000	$15.72M	1.7%	N/A	5.708%
2/13/2024	Armistice Capital LLC	1,088,000	$5.70M	0.1%	-29.8%	2.070%
2/7/2024	Jump Financial LLC	16,737	$88K	0.0%	N/A	0.032%
1/25/2024	Heritage Wealth Management Inc. Texas	10,000	$52K	0.0%	N/A	0.019%
12/6/2023	Citigroup Inc.	67,677	$0.27M	0.0%	N/A	0.129%
11/15/2023	Armistice Capital LLC	1,550,000	$6.06M	0.1%	-61.4%	2.949%
11/14/2023	Prescott Group Capital Management L.L.C.	30,000	$0.12M	0.0%	N/A	0.057%
10/24/2023	Bank of New York Mellon Corp	18,621	$73K	0.0%	N/A	0.038%
8/24/2023	Perceptive Advisors LLC	12,757,562	$52.43M	1.5%	+39.5%	25.747%
8/14/2023	Samsara BioCapital LLC	2,780,261	$11.43M	2.0%	+56.4%	8.733%
8/14/2023	Pura Vida Investments LLC	1,413,242	$5.72M	0.8%	-29.2%	4.439%
8/10/2023	Letko Brosseau & Associates Inc.	31,900	$0.13M	0.0%	N/A	0.100%
2/15/2023	Nantahala Capital Management LLC	2,220,830	$6.97M	0.5%	-1.1%	6.977%
2/14/2023	Pura Vida Investments LLC	2,157,298	$6.77M	0.3%	-14.1%	6.778%
11/15/2022	Pura Vida Investments LLC	2,510,302	$12.58M	0.7%	-2.6%	7.888%
11/14/2022	Boothbay Fund Management LLC	34,721	$0.17M	0.0%	-9.5%	0.109%
11/10/2022	Nantahala Capital Management LLC	2,245,830	$11.25M	0.7%	-5.2%	17.262%
8/16/2022	Pura Vida Investments LLC	2,576,196	$14.56M	0.8%	+394.9%	19.802%
8/16/2022	CVI Holdings LLC	60,822	$0.34M	0.0%	N/A	0.468%
8/15/2022	Nantahala Capital Management LLC	2,369,668	$13.39M	0.7%	N/A	18.214%
8/12/2022	Ensign Peak Advisors Inc	56,229	$0.32M	0.0%	+43.6%	0.432%
8/12/2022	Ikarian Capital LLC	347,338	$1.96M	0.4%	-17.8%	2.670%
5/16/2022	Clearline Capital LP	119,924	$0.48M	0.1%	+84.9%	0.922%
2/14/2022	Clearline Capital LP	64,862	$0.28M	0.0%	N/A	0.499%
2/14/2022	Soleus Capital Management L.P.	10,000	$44K	0.0%	-95.4%	0.077%
2/11/2022	Pentwater Capital Management LP	71,313	$0.31M	0.0%	+122.8%	0.548%
11/16/2021	Two Sigma Advisers LP	58,000	$0.53M	0.0%	+31.8%	0.446%
11/15/2021	Pura Vida Investments LLC	533,417	$4.87M	0.1%	-1.7%	4.103%
11/15/2021	Marshall Wace LLP	12,457	$0.11M	0.0%	-35.5%	0.096%
11/9/2021	BlackRock Inc.	17,818	$0.16M	0.0%	-11.4%	0.137%
11/4/2021	Close Asset Management Ltd	7,000	$64K	0.0%	N/A	0.054%
8/25/2021	Marshall Wace LLP	19,321	$0.16M	0.0%	-58.8%	0.149%
8/18/2021	Ikarian Capital LLC	624,684	$5.02M	0.4%	-20.0%	4.805%
8/17/2021	Walleye Capital LLC	19,093	$0.15M	0.0%	N/A	0.147%
8/17/2021	Millennium Management LLC	155,135	$1.25M	0.0%	N/A	1.193%
8/17/2021	Bridgeway Capital Management LLC	41,900	$0.34M	0.0%	-14.5%	0.322%
8/16/2021	Tibra Equities Europe Ltd	40,000	$0.32M	0.1%	N/A	0.308%
8/16/2021	Marshall Wace LLP	19,321	$0.16M	0.0%	-58.8%	0.149%
8/13/2021	Geode Capital Management LLC	36,102	$0.29M	0.0%	-60.0%	0.278%
8/13/2021	Vanguard Group Inc.	220,029	$1.77M	0.0%	+3.8%	1.692%
8/12/2021	Trexquant Investment LP	11,610	$93K	0.0%	N/A	0.089%
8/12/2021	Ergoteles LLC	31,000	$0.25M	0.0%	N/A	0.238%
8/11/2021	Deutsche Bank AG	76,441	$0.61M	0.0%	-5.4%	0.588%
8/11/2021	Susquehanna International Group LLP	21,529	$0.17M	0.0%	N/A	0.166%
8/2/2021	Advisor Group Holdings Inc.	4,434	$36K	0.0%	-89.6%	0.034%
5/18/2021	Morgan Stanley	107,217	$1.24M	0.0%	+655.0%	0.825%
5/17/2021	Nuveen Asset Management LLC	17,913	$0.21M	0.0%	N/A	0.138%
5/17/2021	Ikarian Capital LLC	780,728	$9.05M	0.3%	-4.2%	6.005%
5/13/2021	Bank of New York Mellon Corp	15,036	$0.17M	0.0%	-22.7%	0.116%
5/13/2021	Blair William & Co. IL	55,000	$0.64M	0.0%	N/A	0.424%
5/12/2021	Northern Trust Corp	64,451	$0.75M	0.0%	-5.2%	0.497%
5/12/2021	Geode Capital Management LLC	90,281	$1.05M	0.0%	+31.8%	0.696%
5/12/2021	JPMorgan Chase & Co.	147,400	$1.71M	0.0%	-22.8%	1.137%
5/7/2021	BlackRock Inc.	348,394	$4.04M	0.0%	+31.9%	2.688%
5/4/2021	Envestnet Asset Management Inc.	36,792	$0.43M	0.0%	N/A	0.284%
2/19/2021	JPMorgan Chase & Co.	191,000	$2.18M	0.0%	+9,858.3%	1.478%
2/16/2021	Charles Schwab Investment Management Inc.	14,177	$0.16M	0.0%	N/A	0.110%
2/13/2021	American International Group Inc.	3,954	$45K	0.0%	+60.9%	0.031%
2/12/2021	Ikarian Capital LLC	815,364	$9.30M	0.4%	+110.2%	6.307%
2/11/2021	Northern Trust Corp	67,995	$0.78M	0.0%	+39.1%	0.526%
2/9/2021	Wells Fargo & Company MN	3,521	$40K	0.0%	+225.1%	0.027%
2/9/2021	Bank of New York Mellon Corp	19,450	$0.22M	0.0%	+24.3%	0.150%
2/5/2021	BlackRock Inc.	264,165	$3.01M	0.0%	+27.4%	2.044%
11/16/2020	ArrowMark Colorado Holdings LLC	788,215	$8.81M	0.1%	+293.8%	6.097%
11/16/2020	Boothbay Fund Management LLC	43,664	$0.49M	0.0%	N/A	0.338%
11/10/2020	State Street Corp	45,506	$0.51M	0.0%	+7.2%	0.352%
11/6/2020	BlackRock Inc.	207,326	$2.32M	0.0%	+1.0%	1.604%
11/5/2020	New York State Common Retirement Fund	4,438	$50K	0.0%	-44.5%	0.034%

Data available starting January 2016

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $0.26

$0.26

$0.29

50 Day Range

MA: $0.27

$0.22

$0.34

52 Week Range

Now: $0.26

$0.21

$6.79

Volume

829,665 shs

Average Volume

1,639,323 shs

Market Capitalization

$16.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lyra Therapeutics?: Lyra Therapeutics' top insider shareholders include:
Perceptive Advisors Llc (Director)
Nbvm Gp, Llc (Major Shareholder)
Harlan Waksal (Insider)
Learn More about top insider investors at Lyra Therapeutics.